<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152871">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01689090</url>
  </required_header>
  <id_info>
    <org_study_id>HypNOCOX</org_study_id>
    <nct_id>NCT01689090</nct_id>
  </id_info>
  <brief_title>Diameter Changes of Retinal Vessels During Hypoxia</brief_title>
  <official_title>Diameter Changes of Retinal Vessels During Hypoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to study if an inhibition of nitric oxide and/or prostaglandins
      affect the diameter changes of retinal vessels observed during hypoxia. Diameter changes are
      studied using the Dynamic Vessel Analyzer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Diameter changes of retinal vessels</measure>
    <time_frame>Examination day 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparing the differences of diameter changes occuring during each of the interventions.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <condition>Retinal Branch Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Hypoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions at two examination days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoxia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions at two examination days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COX inhibitor</intervention_name>
    <description>Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated</description>
    <arm_group_label>Hypoxia</arm_group_label>
    <arm_group_label>Normoxia</arm_group_label>
    <other_name>Eye drops voltaren 1 mg/ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>L-NG-monomethyl arginine citrate</intervention_name>
    <description>Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels</description>
    <arm_group_label>Hypoxia</arm_group_label>
    <arm_group_label>Normoxia</arm_group_label>
    <other_name>L-NMMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COX inhibitor + L-NG-monomethyl arginine citrate</intervention_name>
    <description>Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed</description>
    <arm_group_label>Hypoxia</arm_group_label>
    <arm_group_label>Normoxia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes type 1 without retinopathy

          -  Retinal branch vein occlusion

        Exclusion Criteria:

          -  Cardio-vascular disease

          -  Lung disease

          -  Pregnancy

          -  Previous ocular disease other than retinal branch vein occlusion

          -  Previous treatment with medications influencing on the intraocular pressure or the
             metabolism of nitric oxide or prostaglandins
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Line Pedersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Line Pedersen, MD</last_name>
    <phone>+45 78463250</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ophthalmology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Anoxia</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Cyclooxygenase Inhibitors</mesh_term>
    <mesh_term>Omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
